CML
News
Group ranks TKIs according to cardiotoxicity
Researchers say they have devised a way to rank tyrosine kinase inhibitors (TKIs) based on their likelihood of causing lasting heart damage in...
News
Styrene exposure linked to myeloid leukemia, HL
A new study links styrene—a chemical used in the manufacture of plastics, rubber, and resins—to certain cancers. The research showed that,...
From the Journals
AML leads percent gains in 5-year survival among leukemias
For 2008-2013, the 5-year relative survival rate for all leukemia was 60.1%, compared with 10% in 1950-1954.
News
Study quantifies 5-year survival rates for blood cancers
A new study shows that 5-year survival rates for US patients with hematologic malignancies have increased greatly since the 1950s, but there is...
News
Drugs may be effective against hematologic, other cancers
Image courtesy of PNAS A diabetes medication and an antihypertensive drug may prove effective in the treatment of hematologic malignancies and...
Conference Coverage
Study reveals CML patients likely to benefit from HSCT long-term
Photo by Chad McNeeley SAN DIEGO—New research may help inform the management of patients with chronic myeloid leukemia (CML), according to a...
News
Group estimates global cancer cases, deaths in 2015
receiving chemotherapy Photo by Rhoda Baer Researchers have estimated the global incidence of 32 cancer types and deaths related to these...
Conference Coverage
Half of CML patients can stop TKI therapy, study suggests
© Todd Buchanan 2016 SAN DIEGO—Updated results of the EURO-SKI trial support the idea that certain chronic myeloid leukemia (CML) patients can...
Article
VIDEO: Half-dose TKI safe, cost-effective in CML in stable remission
SAN DIEGO – For some patients with solid stable remissions, halving the TKI dose or even stopping therapy altogether appears to be safe.
Conference Coverage
Halving the TKI dose safe, cost effective in CML patients with stable remissions
SAN DIEGO - For some CML patients with solid, stable remissions, halving their dose of a tyrosine kinase inhibitor – or even stopping therapy...
News
FDA grants full approval for ponatinib
Photo from Business Wire The US Food and Drug Administration (FDA) has granted full approval for the kinase inhibitor ponatinib (Iclusig®) and...